Published in Am J Pathol on October 02, 2008
Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist (2011) 1.90
Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer (2010) 1.64
Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol (2012) 1.44
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer (2015) 1.42
A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg (2013) 1.36
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol (2012) 1.21
Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch (2009) 1.19
Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol (2013) 1.16
Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer (2012) 1.15
High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer (2010) 1.14
Mesenteric fibromatosis. Int J Colorectal Dis (2014) 1.06
Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol (2013) 1.02
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res (2012) 0.95
CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study. PLoS One (2014) 0.95
The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target. Mol Cell Ther (2015) 0.94
β-Catenin mutation status and outcomes in sporadic desmoid tumors. Oncologist (2013) 0.94
Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res (2011) 0.91
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol (2011) 0.90
Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer (2016) 0.90
Intra-abdominal desmoid tumor mimicking locoregional recurrence after colectomy in a patient with sporadic colon cancer: report of a case. Surg Today (2011) 0.89
Current perspectives on desmoid tumors: the mayo clinic approach. Cancers (Basel) (2011) 0.89
Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses. Virchows Arch (2015) 0.89
Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol (2015) 0.88
Efficient Genetic Analysis of Microdissected Samples by Agarose-Bead Method: Alterations of β-Catenin Gene in Fundic Gland Polyp and Heterotopic Gastric Mucosa of Duodenum. Acta Histochem Cytochem (2013) 0.84
Desmoid tumours: our experience of six cases and review of literature. J Clin Diagn Res (2014) 0.84
Primary asymptomatic desmoid tumor of the mesentery. Am J Case Rep (2015) 0.82
Gastrointestinal Mesenchymal Neoplasms other than Gastrointestinal Stromal Tumors: Focusing on Their Molecular Aspects. Patholog Res Int (2011) 0.81
Role of β-catenin expression in paediatric mesenchymal lesions: a tissue microarray-based immunohistochemical study. Eur J Histochem (2012) 0.81
Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer (2012) 0.81
New, tolerable γ-secretase inhibitor takes desmoid down a notch. Clin Cancer Res (2014) 0.81
The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget (2016) 0.81
Genetic analysis of colon tumors induced by a dietary carcinogen PhIP in CYP1A humanized mice: Identification of mutation of β-catenin/Ctnnb1 as the driver gene for the carcinogenesis. Mol Carcinog (2014) 0.80
Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report. World J Surg Oncol (2016) 0.79
Postoperative retroperitoneal desmoid tumor mimics recurrent gastrointestinal stromal tumor: a case report. World J Gastroenterol (2012) 0.79
Pathology of gastrointestinal stromal tumors. Clin Med Insights Pathol (2012) 0.79
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer (2015) 0.78
Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature. Sarcoma (2012) 0.78
Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status. Int J Clin Oncol (2015) 0.78
Desmoid Tumor Formation following Posterior Spinal Instrumentation Placement. Evid Based Spine Care J (2013) 0.77
Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics. Head Neck Pathol (2016) 0.76
Spatio-temporal genetic heterogeneity of CTNNB1 mutations in sporadic desmoid type fibromatosis lesions. Virchows Arch (2015) 0.76
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol (2017) 0.75
A woman with a history of colorectal carcinoma presenting with an abdominal mass. BMJ Case Rep (2013) 0.75
Simple resection of truncal desmoid tumors: A case series. Oncol Lett (2016) 0.75
Intra-Abdominal and Abdominal Wall Desmoid Fibromatosis. Oncol Ther (2016) 0.75
Expression of FAP, ADAM12, WISP1, and SOX11 is heterogeneous in aggressive fibromatosis and spatially relates to the histologic features of tumor activity. Cancer Med (2013) 0.75
Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. BMC Cancer (2016) 0.75
Pancreatic solitary fibrous tumor in a toddler managed by pancreaticoduodenectomy: a case report and review of the literature. Onco Targets Ther (2017) 0.75
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Desmoid tumors: clinical features and treatment options: a case report and a review of literature. Pan Afr Med J (2015) 0.75
Clinical significance of midkine expression in sporadic desmoid tumors. Oncol Lett (2016) 0.75
Successful outcome after laparoscopic surgery for sporadic colonic desmoid tumor with β-catenin mutation: a case report. J Med Case Rep (2013) 0.75
Characteristics of cultured desmoid cells with different CTNNB1 mutation status. Cancer Med (2015) 0.75
A Mesenteric Desmoid Tumor with Rapid Progression. Intern Med (2017) 0.75
MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol (2015) 0.75
Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis. Virchows Arch (2012) 0.75
[Molecular methods in the diagnosis of sarcoma]. Pathologe (2011) 0.75
Does routine colonoscopy help diagnose familial adenomatous polyposis in patients presenting with desmoid tumors but no gastrointestinal symptoms? Int J Colorectal Dis (2016) 0.75
Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol (2017) 0.75
Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations. Oncotarget (2017) 0.75
Wnt/beta-catenin signaling in development and disease. Cell (2006) 30.09
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 6.29
Wnt signaling: is the party in the nucleus? Genes Dev (2006) 4.10
The oncogenic activation of beta-catenin. Curr Opin Genet Dev (1999) 3.87
Beta-catenin: a key mediator of Wnt signaling. Curr Opin Genet Dev (1998) 3.65
Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol (1999) 3.18
The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol (1982) 2.83
The enigma of desmoid tumors. Ann Surg (1999) 2.57
Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol (2006) 2.53
Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol (1997) 2.34
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res (1999) 2.18
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology (2007) 1.97
beta-Catenin signaling in biological control and cancer. J Cell Biochem (2007) 1.89
Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol (2005) 1.88
Mechanistic insights from structural studies of beta-catenin and its binding partners. J Cell Sci (2007) 1.76
Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol (2002) 1.74
Chest-wall desmoid tumors: results of surgical intervention. Ann Thorac Surg (2004) 1.70
Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol (2003) 1.68
Nuclear beta-catenin in mesenchymal tumors. Mod Pathol (2005) 1.60
Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest (2007) 1.51
Management of desmoid tumors. Surg Gynecol Obstet (1989) 1.45
Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet (1996) 1.39
Combination chemotherapy in adult desmoid tumors. Cancer (1993) 1.36
Wnt signaling as a therapeutic target for cancer. Methods Mol Biol (2007) 1.34
Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res (1998) 1.31
Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol (2005) 1.25
Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol (2008) 1.24
The efficacy of radiotherapy as postoperative treatment for desmoid tumors. Int J Radiat Oncol Biol Phys (2001) 1.18
Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol (2005) 1.17
Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys (1983) 1.17
Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg (2004) 1.12
Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. Am J Surg Pathol (2007) 1.12
Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol (2002) 1.12
Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology (2007) 1.04
The management of desmoid tumors. Int J Radiat Oncol Biol Phys (1993) 1.02
The management of extra-abdominal desmoid tumours. Int Orthop (2004) 1.01
The diagnostic value of beta-catenin immunohistochemistry. Adv Anat Pathol (2005) 0.97
beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours. J Pathol (2001) 0.96
APC gene mutations and extraintestinal phenotype of familial adenomatous polyposis. Gut (1997) 0.95
Radiation therapy for aggressive fibromatosis. The Experience at the University of Florida. J Bone Joint Surg Am (1991) 0.95
A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol (1999) 0.94
Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction. Lab Invest (2002) 0.93
APC mutations in FAP-associated desmoid tumours are non-random but not 'just right'. Hum Mol Genet (2006) 0.92
Familial adenomatous polyposis: from bedside to benchside. Am J Clin Pathol (1998) 0.89
Desmoid tumors in adults: the role of radiotherapy in their management. Am J Surg (1988) 0.88
Aggressive fibromatosis: optimisation of local management with a retrospective failure analysis. Radiother Oncol (1995) 0.88
Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis. Pathology (2007) 0.88
Difference in characteristics of APC mutations between colonic and extracolonic tumors of FAP patients: variations with phenotype. Int J Cancer (2008) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol (2006) 2.87
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Soft tissue sarcomas. CA Cancer J Clin (2004) 2.65
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am J Surg Pathol (2008) 2.58
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer (2002) 2.33
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res (2010) 2.11
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Angiosarcoma of the breast. Cancer (2005) 1.98
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol (2011) 1.91
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One (2010) 1.87
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
Increasing the pool of academically oriented African-American medical and surgical oncologists. Cancer (2003) 1.77
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Robot-assisted transaxillary thyroid surgery in the United States: is it comparable to open thyroid lobectomy? Ann Surg Oncol (2011) 1.62
Texas hospitals' experience with the Texas Advance Directives Act. Crit Care Med (2007) 1.59
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53
Lymphoproliferative disorders in Costa Rica and simian virus 40. Haematologica (2005) 1.53
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg (2003) 1.45
Accuracy of preoperative percutaneous biopsy for the diagnosis of retroperitoneal liposarcoma subtypes. Ann Surg Oncol (2014) 1.44
Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol (2004) 1.41
Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One (2009) 1.40
Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res (2009) 1.40
Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther (2007) 1.36
Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol (2013) 1.35
Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg (2002) 1.35
Soft tissue sarcoma. J Natl Compr Canc Netw (2010) 1.34
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther (2009) 1.33
Angiosarcoma: clinical and molecular insights. Ann Surg (2010) 1.33
Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Mod Pathol (2009) 1.29
Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med (2009) 1.28
Genetic aberrations in soft tissue leiomyosarcoma. Cancer Lett (2008) 1.28
P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget (2013) 1.26
Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer (2003) 1.24
MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res (2012) 1.24
Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg (2006) 1.23
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol (2012) 1.21
Noncontact measurement of elasticity for the detection of soft-tissue tumors using phase-sensitive optical coherence tomography combined with a focused air-puff system. Opt Lett (2012) 1.21
An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest (2010) 1.19
Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res (2011) 1.19
Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res (2007) 1.18
The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer (2002) 1.18
Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin North Am (2008) 1.17
Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer (2009) 1.17
New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort. Drug Resist Updat (2010) 1.15
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A (2008) 1.14
CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer (2013) 1.13
Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.13
Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr (2014) 1.12
Osteosarcoma in a patient with McCune-Albright syndrome and Mazabraud's syndrome: a case report emphasizing the cytological and cytogenetic findings. Hum Pathol (2003) 1.10
Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys (2006) 1.10
Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res (2008) 1.09
MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am J Surg Pathol (2012) 1.08
Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer (2007) 1.08
TNFα cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One (2011) 1.08
The role of surgical margin status in retroperitoneal sarcoma. J Surg Oncol (2008) 1.08
Staging soft tissue sarcoma: evolution and change. CA Cancer J Clin (2006) 1.08
Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol (2011) 1.08
Surgical management of soft tissue sarcomas of the hand and foot. Cancer (2002) 1.07